Skip to main content

Hemab Therapeutics Holdings, Inc.

COAG
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002114044

No open-market purchases or sales by Hemab Therapeutics Holdings, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; Soros Fund Management is the only superinvestor holding it.

Holders of 5% or more of COAG

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Hemab Therapeutics Holdings, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of COAG
HolderLatest formStakeChangeFirst filedLatest filingFiling
Ra Capital Management, L.P.13G16.60%7.73M sharesNewMay 11, 20261 filingMay 11, 2026SEC
AI Den-Mab LLC13D10.40%4.88M sharesNewMay 11, 20261 filingMay 11, 2026SEC
Novo Holdings A/S13G9.00%4.18M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Deep Track Capital, LP13G8.15%3.60M sharesNewMay 8, 20261 filingMay 8, 2026SEC
FMR LLC13G7.90%3.70M sharesNewAug 6, 20261 filingAug 6, 2026SEC
Capital International Investors13G7.70%3.60M sharesNewAug 12, 20261 filingAug 12, 2026SEC
Avoro Capital Advisors LLC13G7.06%3.30M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Sofinnova Crossover II S.L.P.13G5.40%2.51M sharesNewAug 5, 20261 filingAug 5, 2026SEC
Invus Global Management, LLC13G5.10%2.37M sharesNewAug 7, 20261 filingAug 7, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

9 Schedule 13D and 13G filings on Hemab Therapeutics Holdings, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on COAG
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20265:05 PM ETNovo Holdings A/S13G9.00%4.18M sharesNewJun 30, 2026SEC
Aug 14, 20269:01 AM ETAvoro Capital Advisors LLCand 2 others13G7.06%3.30M sharesNewJun 30, 2026SEC
Aug 12, 202610:28 AM ETCapital International Investors13G7.70%3.60M sharesNewJun 30, 2026SEC
Aug 7, 20269:31 AM ETInvus Global Management, LLCand 7 others13G5.10%2.37M sharesNewAug 3, 2026SEC
Aug 6, 202610:28 AM ETFMR LLCand 1 other13G7.90%3.70M sharesNewJun 30, 2026SEC
Aug 5, 202610:38 AM ETSofinnova Crossover II S.L.P.and 6 others13G5.40%2.51M sharesNewJun 30, 2026SEC
May 11, 20265:46 PM ETRa Capital Management, L.P.and 3 others13G16.60%7.73M sharesNewMay 4, 2026SEC
May 11, 20264:43 PM ETAI Den-Mab LLCand 4 others13D10.40%4.88M sharesNewMay 4, 2026SEC
May 8, 20264:18 PM ETDeep Track Capital, LPand 3 others13G8.15%3.60M sharesNewMay 1, 2026SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Hemab Therapeutics Holdings, Inc. shares.

No Form 144 notices for Hemab Therapeutics Holdings, Inc. are on file.